Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 90 articles:
HTML format



Single Articles


    January 2021
  1. LAYTRAGOON LEWIN N, Karlsson JE, Robinsson D, Fagerberg M, et al
    Influence of single nucleotide polymorphisms among cigarette smoking and non-smoking patients with coronary artery disease, urinary bladder cancer and lung cancer.
    PLoS One. 2021;16:e0243084.
    PubMed     Abstract available


  2. BESSA A, Rammant E, Enting D, Bryan RT, et al
    The need for supportive mental wellbeing interventions in bladder cancer patients: A systematic review of the literature.
    PLoS One. 2021;16:e0243136.
    PubMed     Abstract available


  3. LIEDBERG F, Hagberg O, Aljabery F, Gardmark T, et al
    Cumulative incidence of midline incisional hernia and its surgical treatment after radical cystectomy and urinary diversion for bladder cancer: A nation-wide population-based study.
    PLoS One. 2021;16:e0246703.
    PubMed     Abstract available


  4. HUANG CY, Wang SC, Chan L, Hsieh TY, et al
    Gender differences in trends of bladder cancer mortality-to-incidence ratios according to health expenditure in 55 countries.
    PLoS One. 2021;16:e0244510.
    PubMed     Abstract available


  5. UYSAL D, Kowalewski KF, Kriegmair MC, Wirtz R, et al
    A comprehensive molecular characterization of the 8q22.2 region reveals the prognostic relevance of OSR2 mRNA in muscle invasive bladder cancer.
    PLoS One. 2021;16:e0248342.
    PubMed     Abstract available


  6. WANG K, Yang JC, Jang YJ, Chen GY, et al
    19-(Benzyloxy)-19-oxojolkinolide B (19-BJB), an ent-abietane diterpene diepoxide, inhibits the growth of bladder cancer T24 cells through DNA damage.
    PLoS One. 2021;16:e0248468.
    PubMed     Abstract available


  7. JIANG H, Gu X, Zuo Z, Tian G, et al
    Prognostic value of circulating tumor cells in patients with bladder cancer: A meta-analysis.
    PLoS One. 2021;16:e0254433.
    PubMed     Abstract available


  8. MUILWIJK T, Akand M, Daelemans S, Marien K, et al
    Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer.
    PLoS One. 2021;16:e0257195.
    PubMed     Abstract available


    January 2020
  9. CHEN Q, Fu L
    Upregulation of long non-coding RNA ROR1-AS1 promotes cell growth and migration in bladder cancer by regulation of miR-504.
    PLoS One. 2020;15:e0227568.
    PubMed     Abstract available


  10. EVERS J, Grotenhuis AJ, Aben KKH, Kiemeney LALM, et al
    No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression.
    PLoS One. 2020;15:e0229384.
    PubMed     Abstract available


  11. REZAEE ME, Lynch KE, Li Z, MacKenzie TA, et al
    The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
    PLoS One. 2020;15:e0230417.
    PubMed     Abstract available


  12. LILLESAND M, Kvikstad V, Mangrud OM, Gudlaugsson E, et al
    Mitotic activity index and CD25+ lymphocytes predict risk of stage progression in non-muscle invasive bladder cancer.
    PLoS One. 2020;15:e0233676.
    PubMed     Abstract available


  13. PACKEISER EM, Hewicker-Trautwein M, Thiemeyer H, Mohr A, et al
    Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.
    PLoS One. 2020;15:e0230272.
    PubMed     Abstract available


  14. HANKE M, Dubois J, Kausch I, Petkovic S, et al
    Oncoprotein 18 is necessary for malignant cell proliferation in bladder cancer cells and serves as a G3-specific non-invasive diagnostic marker candidate in urinary RNA.
    PLoS One. 2020;15:e0229193.
    PubMed     Abstract available


  15. MEHUS AA, Bergum N, Knutson P, Shrestha S, et al
    Activation of PPARgamma and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells.
    PLoS One. 2020;15:e0237976.
    PubMed     Abstract available


  16. HUTTANUS HM, Vu T, Guruli G, Tracey A, et al
    Raman chemometric urinalysis (Rametrix) as a screen for bladder cancer.
    PLoS One. 2020;15:e0237070.
    PubMed     Abstract available


  17. SANTOS-SANCHEZ V, Cordoba-Dona JA, Viciana F, Escolar-Pujolar A, et al
    Geographical variations in cancer mortality and social inequalities in southern Spain (Andalusia). 2002-2013.
    PLoS One. 2020;15:e0233397.
    PubMed     Abstract available


  18. REED O, Jubber I, Griffin J, Noon AP, et al
    Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes.
    PLoS One. 2020;15:e0239338.
    PubMed     Abstract available


  19. TELEKA S, Hindy G, Drake I, Poveda A, et al
    Blood pressure and bladder cancer risk in men by use of survival analysis and in interaction with NAT2 genotype, and by Mendelian randomization analysis.
    PLoS One. 2020;15:e0241711.
    PubMed     Abstract available


  20. AZUMA T, Sato Y, Ohno T, Azuma M, et al
    Serum soluble B7-H3 is a prognostic marker for patients with non-muscle-invasive bladder cancer.
    PLoS One. 2020;15:e0243379.
    PubMed     Abstract available



  21. Retraction: MicroRNA-214 Suppresses Oncogenesis and Exerts Impact on Prognosis by Targeting PDRG1 in Bladder Cancer.
    PLoS One. 2020;15:e0244274.
    PubMed    


  22. KARDOS J, Rose TL, Manocha U, Wobker SE, et al
    Development and validation of a NanoString BASE47 bladder cancer gene classifier.
    PLoS One. 2020;15:e0243935.
    PubMed     Abstract available


    January 2019
  23. YOSHINO T, Miyazaki J, Kojima T, Kandori S, et al
    Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guerin induce antitumor immunity in a syngeneic murine bladder cancer model.
    PLoS One. 2019;14:e0209196.
    PubMed     Abstract available


  24. APOLLO A, Ortenzi V, Scatena C, Zavaglia K, et al
    Molecular characterization of low grade and high grade bladder cancer.
    PLoS One. 2019;14:e0210635.
    PubMed     Abstract available


  25. BYUN SJ, Park W, Cho KH, Cho J, et al
    A multi-institutional study of bladder-preserving therapy for stage II-IV bladder cancer: A Korean Radiation Oncology Group Study (KROG 14-16).
    PLoS One. 2019;14:e0209998.
    PubMed     Abstract available


  26. HASNAIN Z, Mason J, Gill K, Miranda G, et al
    Machine learning models for predicting post-cystectomy recurrence and survival in bladder cancer patients.
    PLoS One. 2019;14:e0210976.
    PubMed     Abstract available


  27. SIMON M, Bosset PO, Rouanne M, Benhamou S, et al
    Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score.
    PLoS One. 2019;14:e0211721.
    PubMed     Abstract available


  28. BAUSCH K, Roth E, Heinz S, Horst D, et al
    Urinary Calprotectin loses specificity as tumour marker due to sterile leukocyturia associated with bladder cancer.
    PLoS One. 2019;14:e0213549.
    PubMed     Abstract available


  29. WETTSTEIN MS, Rooprai JK, Pazhepurackel C, Wallis CJD, et al
    Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?
    PLoS One. 2019;14:e0216255.
    PubMed     Abstract available


  30. LIU W, Woolbright BL, Pirani K, Didde R, et al
    Tumor M2-PK: A novel urine marker of bladder cancer.
    PLoS One. 2019;14:e0218737.
    PubMed     Abstract available


  31. JIANG WD, Yuan PC
    Molecular network-based identification of competing endogenous RNAs in bladder cancer.
    PLoS One. 2019;14:e0220118.
    PubMed     Abstract available


  32. KAWAHARA T, Kojima T, Kandori S, Kurobe M, et al
    TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer.
    PLoS One. 2019;14:e0220173.
    PubMed     Abstract available


  33. WANG CC, Tsai YC, Jeng YM
    Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer.
    PLoS One. 2019;14:e0221785.
    PubMed     Abstract available


  34. ZHU Z, Zhao J, Li Y, Pang C, et al
    Prognostic value of preoperative hydronephrosis in patients with bladder cancer undergoing radical cystectomy: A meta-analysis.
    PLoS One. 2019;14:e0222223.
    PubMed     Abstract available


  35. FANG CW, Hsieh VC, Huang SK, Tsai IJ, et al
    A population-based cohort study examining the association of documented bladder diverticulum and bladder cancer risk in urology patients.
    PLoS One. 2019;14:e0222875.
    PubMed     Abstract available


  36. KIM MJ, Chi BH, Yoo JJ, Ju YM, et al
    Structure establishment of three-dimensional (3D) cell culture printing model for bladder cancer.
    PLoS One. 2019;14:e0223689.
    PubMed     Abstract available


  37. GRIFFITHS GO, Cowan RA, Grigor KM, Uscinska BM, et al
    BA08: An open-label, single-arm, non-randomised, phase 2 trial of cisplatin, methotrexate and vinblastine (CMV) for pure squamous cell cancer of the urinary tract.
    PLoS One. 2019;14:e0210785.
    PubMed     Abstract available


  38. GOFRIT ON, Klein BY, Cohen IR, Ben-Hur T, et al
    Bacillus Calmette-Guerin (BCG) therapy lowers the incidence of Alzheimer's disease in bladder cancer patients.
    PLoS One. 2019;14:e0224433.
    PubMed     Abstract available


  39. HE S, Carman CV, Lee JH, Lan B, et al
    The tumor suppressor p53 can promote collective cellular migration.
    PLoS One. 2019;14:e0202065.
    PubMed     Abstract available


  40. RYTLEWSKI J, Deng S, Xie T, Davis C, et al
    Model to improve specificity for identification of clinically-relevant expanded T cells in peripheral blood.
    PLoS One. 2019;14:e0213684.
    PubMed     Abstract available


  41. ETO S, Saeki K, Yoshitake R, Yoshimoto S, et al
    Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells.
    PLoS One. 2019;14:e0218382.
    PubMed     Abstract available


  42. ABECASSIS J, Hamy AS, Laurent C, Sadacca B, et al
    Assessing reliability of intra-tumor heterogeneity estimates from single sample whole exome sequencing data.
    PLoS One. 2019;14:e0224143.
    PubMed     Abstract available


    January 2018
  43. HAN S, Kim D, Shivakumar M, Lee YJ, et al
    The effects of alternative splicing on miRNA binding sites in bladder cancer.
    PLoS One. 2018;13:e0190708.
    PubMed     Abstract available


  44. SATHE A, Chalaud G, Oppolzer I, Wong KY, et al
    Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
    PLoS One. 2018;13:e0190854.
    PubMed     Abstract available


  45. KIM M, Oh SJ, Kwak C, Kim HH, et al
    Psychometric validation study of the Korean version of the Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index.
    PLoS One. 2018;13:e0190570.
    PubMed     Abstract available


  46. BARBOSA ALA, Vermeulen SHHM, Aben KK, Grotenhuis AJ, et al
    Smoking intensity and bladder cancer aggressiveness at diagnosis.
    PLoS One. 2018;13:e0194039.
    PubMed     Abstract available


  47. XIA Y, Liu Z, Yu W, Zhou S, et al
    The prognostic significance of long noncoding RNAs in bladder cancer: A meta-analysis.
    PLoS One. 2018;13:e0198602.
    PubMed     Abstract available


  48. BECKFORD VERA DR, Smith CC, Bixby LM, Glatt DM, et al
    Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors.
    PLoS One. 2018;13:e0193832.
    PubMed     Abstract available


  49. HARTANA CA, Ahlen Bergman E, Zirakzadeh AA, Krantz D, et al
    Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGFbeta2 mediated pathway.
    PLoS One. 2018;13:e0200079.
    PubMed     Abstract available


  50. FERDOSI S, Ho TH, Castle EP, Stanton ML, et al
    Behavior of blood plasma glycan features in bladder cancer.
    PLoS One. 2018;13:e0201208.
    PubMed     Abstract available


  51. SUTTON AJ, Lamont JV, Evans RM, Williamson K, et al
    An early analysis of the cost-effectiveness of a diagnostic classifier for risk stratification of haematuria patients (DCRSHP) compared to flexible cystoscopy in the diagnosis of bladder cancer.
    PLoS One. 2018;13:e0202796.
    PubMed     Abstract available


  52. GARCZYK S, Schneider U, Lurje I, Becker K, et al
    ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
    PLoS One. 2018;13:e0202965.
    PubMed     Abstract available


  53. MURAI R, Itoh Y, Kageyama S, Nakayama M, et al
    Prediction of intravesical recurrence of non-muscle-invasive bladder cancer by evaluation of intratumoral Foxp3+ T cells in the primary transurethral resection of bladder tumor specimens.
    PLoS One. 2018;13:e0204745.
    PubMed     Abstract available


  54. BERLE M, Ghila L, Vethe H, Chaudhry A, et al
    Novel protein signatures suggest progression to muscular invasiveness in bladder cancer.
    PLoS One. 2018;13:e0206475.
    PubMed     Abstract available


  55. YUK HD, Jeong CW, Kwak C, Kim HH, et al
    Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
    PLoS One. 2018;13:e0208267.
    PubMed     Abstract available


  56. BOSSCHIETER J, Bach S, Bijnsdorp IV, Segerink LI, et al
    A protocol for urine collection and storage prior to DNA methylation analysis.
    PLoS One. 2018;13:e0200906.
    PubMed     Abstract available


  57. LU DL, Ren ZJ, Zhang Q, Ren PW, et al
    Meta-analysis of the association between the inflammatory potential of diet and urologic cancer risk.
    PLoS One. 2018;13:e0204845.
    PubMed     Abstract available


  58. YU A, Mansure JJ, Solanki S, Siemens DR, et al
    Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy.
    PLoS One. 2018;13:e0205746.
    PubMed     Abstract available


    January 2017
  59. MATSUO T, Miyata Y, Asai A, Sagara Y, et al
    Green Tea Polyphenol Induces Changes in Cancer-Related Factors in an Animal Model of Bladder Cancer.
    PLoS One. 2017;12:e0171091.
    PubMed     Abstract available


  60. XIONG Y, Li J, Ma S, Ge J, et al
    A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer.
    PLoS One. 2017;12:e0170819.
    PubMed     Abstract available


  61. SHIN SS, Song JH, Hwang B, Noh DH, et al
    HSPA6 augments garlic extract-induced inhibition of proliferation, migration, and invasion of bladder cancer EJ cells; Implication for cell cycle dysregulation, signaling pathway alteration, and transcription factor-associated MMP-9 regulation.
    PLoS One. 2017;12:e0171860.
    PubMed     Abstract available


  62. VAN KESSEL KE, van de Werken HJ, Lurkin I, Ziel-van der Made AC, et al
    A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.
    PLoS One. 2017;12:e0174039.
    PubMed     Abstract available


  63. IDE H, Inoue S, Miyamoto H
    Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies.
    PLoS One. 2017;12:e0174746.
    PubMed     Abstract available


  64. XIE JY, Chen PC, Zhang JL, Gao ZS, et al
    The prognostic significance of DAPK1 in bladder cancer.
    PLoS One. 2017;12:e0175290.
    PubMed     Abstract available


  65. ORRE M, Latorzeff I, Flechon A, Roubaud G, et al
    Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study.
    PLoS One. 2017;12:e0174978.
    PubMed     Abstract available


  66. HORI S, Miyake M, Tatsumi Y, Onishi S, et al
    Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.
    PLoS One. 2017;12:e0175494.
    PubMed     Abstract available


  67. REULEN RC, de Vogel S, Zhong W, Zhong Z, et al
    Physical activity and risk of prostate and bladder cancer in China: The South and East China case-control study on prostate and bladder cancer.
    PLoS One. 2017;12:e0178613.
    PubMed     Abstract available


  68. AFSHARI M, Janbabaei G, Bahrami MA, Moosazadeh M, et al
    Opium and bladder cancer: A systematic review and meta-analysis of the odds ratios for opium use and the risk of bladder cancer.
    PLoS One. 2017;12:e0178527.
    PubMed     Abstract available


  69. SU YL, Hsieh MC, Chiang PH, Sung MT, et al
    Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma.
    PLoS One. 2017;12:e0169657.
    PubMed     Abstract available


  70. DROOP J, Szarvas T, Schulz WA, Niedworok C, et al
    Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma.
    PLoS One. 2017;12:e0176287.
    PubMed     Abstract available


  71. HUANG P, Lan M, Peng AF, Yu QF, et al
    Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer.
    PLoS One. 2017;12:e0183835.
    PubMed     Abstract available


  72. DOWELL AC, Cobby E, Wen K, Devall AJ, et al
    Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.
    PLoS One. 2017;12:e0184841.
    PubMed     Abstract available


  73. DAI YC, Wang SC, Haque MM, Lin WH, et al
    The interaction of arsenic and N-butyl-N-(4-hydroxybutyl)nitrosamine on urothelial carcinogenesis in mice.
    PLoS One. 2017;12:e0186214.
    PubMed     Abstract available


  74. HUANG JY, Wang R, Gao YT, Yuan JM, et al
    ABO blood type and the risk of cancer - Findings from the Shanghai Cohort Study.
    PLoS One. 2017;12:e0184295.
    PubMed     Abstract available


  75. KWAK YK, Lee SW, Kay CS, Park HH, et al
    Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose.
    PLoS One. 2017;12:e0183339.
    PubMed     Abstract available


  76. GROMOVA I, Svensson S, Gromov P, Moreira JMA, et al
    Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer.
    PLoS One. 2017;12:e0188827.
    PubMed     Abstract available


  77. SASAKI N, Ishi K, Kudo N, Nakayama SMM, et al
    Spatial and temporal profile of cisplatin delivery by ultrasound-assisted intravesical chemotherapy in a bladder cancer model.
    PLoS One. 2017;12:e0188093.
    PubMed     Abstract available


  78. BOGNAR Z, Fekete K, Antus C, Hocsak E, et al
    Desethylamiodarone-A metabolite of amiodarone-Induces apoptosis on T24 human bladder cancer cells via multiple pathways.
    PLoS One. 2017;12:e0189470.
    PubMed     Abstract available


  79. TAE BS, Jeong CW, Kwak C, Kim HH, et al
    Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
    PLoS One. 2017;12:e0189354.
    PubMed     Abstract available


  80. LINDQUIST KJ, Sanford T, Friedlander TW, Paris PL, et al
    Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors.
    PLoS One. 2017;12:e0187975.
    PubMed     Abstract available


    January 2016
  81. GARCIA MM, Gottschalk AR, Brajtbord J, Konety BR, et al
    Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes.
    PLoS One. 2016;11:e0164558.
    PubMed     Abstract available


  82. XIE J, Codd C, Mo K, He Y, et al
    Differential Adverse Event Profiles Associated with BCG as a Preventive Tuberculosis Vaccine or Therapeutic Bladder Cancer Vaccine Identified by Comparative Ontology-Based VAERS and Literature Meta-Analysis.
    PLoS One. 2016;11:e0164792.
    PubMed     Abstract available


  83. KIM D, Choi Y, Ireland J, Foreman O, et al
    Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers.
    PLoS One. 2016;11:e0165856.
    PubMed     Abstract available


  84. LIMA L, Gaiteiro C, Peixoto A, Soares J, et al
    Reference Genes for Addressing Gene Expression of Bladder Cancer Cell Models under Hypoxia: A Step Towards Transcriptomic Studies.
    PLoS One. 2016;11:e0166120.
    PubMed     Abstract available


  85. LONG X, Zu X, Li Y, He W, et al
    Epidermal Growth Factor Receptor and Ki-67 as Predictive Biomarkers Identify Patients Who Will Be More Sensitive to Intravesical Instillations for the Prevention of Bladder Cancer Recurrence after Radical Nephroureterectomy.
    PLoS One. 2016;11:e0166884.
    PubMed     Abstract available


  86. DAI L, Ma C, Zhang Z, Zeng S, et al
    DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0167228.
    PubMed     Abstract available


  87. KANEMOTO K, Fukuta K, Kawai N, Tozawa K, et al
    Genomic Landscape of Experimental Bladder Cancer in Rodents and Its Application to Human Bladder Cancer: Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype.
    PLoS One. 2016;11:e0167374.
    PubMed     Abstract available


  88. WU Z, Wang C, Zhang Z, Liu W, et al
    High Expression of Derlin-1 Is Associated with the Malignancy of Bladder Cancer in a Chinese Han Population.
    PLoS One. 2016;11:e0168351.
    PubMed     Abstract available


  89. LI M, Wang L
    The Associations of Psychological Stress with Depressive and Anxiety Symptoms among Chinese Bladder and Renal Cancer Patients: The Mediating Role of Resilience.
    PLoS One. 2016;11:e0154729.
    PubMed     Abstract available


  90. MASOOMPOUR SM, Lankarani KB, Honarvar B, Tabatabaee SH, et al
    Changing Epidemiology of Common Cancers in Southern Iran, 2007-2010: A Cross Sectional Study.
    PLoS One. 2016;11:e0155669.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: